"Glucagon-Like Peptide 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
| Descriptor ID |
D052216
|
| MeSH Number(s) |
D06.472.317.469.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide 1".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide 1".
This graph shows the total number of publications written about "Glucagon-Like Peptide 1" by people in this website by year, and whether "Glucagon-Like Peptide 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucagon-Like Peptide 1" by people in Profiles.
-
Havranek B, Loh R, Torre B, Redfield R, Halegoua-DeMarzio D. Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes. Sci Rep. 2025 02 10; 15(1):4947.
-
Parkman HP, Rim DS, Anolik JR, Dadparvar S, Maurer AH. Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly-Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying. J Nucl Med Technol. 2024 Mar 05; 52(1):3-7.
-
Lin TY, Kang EY, Shao SC, Lai EC, Garg SJ, Chen KJ, Kang JH, Wu WC, Lai CC, Hwang YS. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Diabetes Metab J. 2023 05; 47(3):394-404.
-
Wai KM, Saroj N, Boucher N, Aggarwal N, Ho AC, Rahimy E. Evaluating the Effect of Hypoglycemic Agents on Diabetic Retinopathy Progression. Ophthalmic Surg Lasers Imaging Retina. 2023 03; 54(3):158-165.
-
Danowitz M, De Leon DD. The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism. Front Endocrinol (Lausanne). 2022; 13:863184.
-
Vernet E, Pedersen M?, Th?gersen H, Shaw AC. Engineering Xaa-Pro dipeptidyl aminopeptidase for specific cleavage of glucagon and glucagon-like peptide 1 from fusion proteins. Protein Expr Purif. 2020 06; 170:105590.
-
Bouhlal S, Ellefsen KN, Sheskier MB, Singley E, Pirard S, Gorelick DA, Huestis MA, Leggio L. Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses. Drug Alcohol Depend. 2017 11 01; 180:68-75.
-
Hansen M, Scheltema MJ, Sonne DP, Hansen JS, Sperling M, Rehfeld JF, Holst JJ, Vilsb?ll T, Knop FK. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. Diabetes Obes Metab. 2016 06; 18(6):571-80.
-
Carlson KR, Pomerantz SC, Li J, Vafa O, Naso M, Strohl W, Mains RE, Eipper BA. Secretion of Fc-amidated peptide fusion proteins by Chinese hamster ovary cells. BMC Biotechnol. 2015 Jun 27; 15:61.
-
Manning PJ, Sutherland WH, Manning AE, de Jong SA, Berry EA. Ingestion of thermally oxidized sunflower oil decreases postprandial lipemia mainly in younger individuals. Nutr Res. 2013 Sep; 33(9):711-8.